Lidocaine Accord Healthcare

Lidocaine, the active ingredient in Lidocaine Accord Healthcare, is a local anesthetic presented as a sterile injectable solution for infiltration and intravenous use. It provides local infiltration anesthesia, nerve block anesthesia, and intravenous anti‑arrhythmic therapy in surgical and cardiac settings.

GNH USA supplies Lidocaine Accord Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lidocaine is used to produce reversible loss of sensation in tissues by blocking sodium channels, making it valuable for several clinical applications.

- Local infiltration anesthesia: provides numbing of targeted tissue for minor surgical or diagnostic procedures. - Nerve block anesthesia: enables regional anesthesia for surgical or diagnostic interventions requiring prolonged analgesia. - Intravenous anti‑arrhythmic therapy: used to manage certain cardiac arrhythmias by stabilizing myocardial electrical activity.

Adverse reactions may occur following administration of lidocaine. The frequency and severity vary with dose, route, and patient factors.

Common Side Effects: - Tingling or numbness at the injection site - Mild hypotension - Dizziness or light‑headedness

Serious or Rare Side Effects: - Methemoglobinemia - Severe cardiac conduction disturbances, including bradycardia or heart block - Anaphylactic reaction or severe allergic response

Lidocaine should be used with careful clinical assessment and monitoring to minimize risks. - Cardiac history: evaluate for pre‑existing conduction abnormalities before use. - Blood pressure: monitor for hypotension during and after administration. - Allergy: avoid in patients with known lidocaine hypersensitivity. - Hepatic function: adjust use in patients with significant liver impairment. - Elderly patients: consider reduced dosage due to altered pharmacokinetics. - Store at ambient temperature: keep in original container, protect from light and moisture.

Lidocaine may interact with other medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine): may increase risk of cardiac toxicity. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise lidocaine plasma concentrations.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may potentiate bradycardic effects. - Calcium channel blockers: can enhance negative inotropic actions. - Diuretics causing electrolyte imbalance: may predispose to arrhythmias when combined with lidocaine.